Clinical Trials Browser

Phase 2/3 × INDUSTRY × Sodium Chloride × Clear all

NCT02641639 2025-03-24

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Phase 2/3 Terminated

70 enrolled 16 charts

Platinum Resistant Ovarian Cancer